Hualan Biological Engineering Inc. (SHE:002007)

Market Cap	27.96B -7.9%
Revenue (ttm)	4.27B -13.3%
Net Income	948.62M -29.1%
EPS	0.52 -29.0%
Shares Out	1.83B
PE Ratio	29.46
Forward PE	16.11
Dividend	0.50 (3.27%)
Ex-Dividend Date	Oct 27, 2025

Volume	10,949,996
Average Volume	11,330,426
Open	15.20
Previous Close	15.28
Day's Range	15.11 - 15.34
52-Week Range	14.94 - 18.39
Beta	0.47
RSI	47.01
Earnings Date	Mar 28, 2026

About SHE:002007

Hualan Biological Engineering Inc. researches, develops, produces, and commercializes blood products, vaccines, and genetic engineering products in China and internationally. The company offers human serum albumin to treat blood loss trauma, shock caused by burns, intracranial pressure and persistent, liver cirrhosis, and kidney disease; edema for hypoproteinemia, neonatal hyperbilirubinemia, cardiopulmonary bypass, adjuvant treatment of burns, hemodialysis, and human respiratory distress syndrome; intravenous human immunoglobulin (pH4) for imm...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 4,012
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002007

Financial Performance

In 2024, SHE:002007's revenue was 4.38 billion, a decrease of -18.02% compared to the previous year's 5.34 billion. Earnings were 1.09 billion, a decrease of -26.57%.